Ingredients by Nature has announced the results of a study on its triple-patented, lemon flavonoid blend, Eriomin, as a nutritional adjunct to metformin.
Eriomin is a standardised citrus flavonoid blend primarily composed of eriocitrin.
It holds three US patents and represents a promising adjunct for pharmaceutical developers, healthcare practitioners, dietary supplement manufacturers and food and beverage formulators.
The research, published in Frontiers in Nutrition, is a groundbreaking clinical trial that demonstrated Eriomin was a safe and effective nutritional adjunct to metformin in the early management of hyperglycaemia.
The 26-week, double-blind, randomised, placebo-controlled crossover study, involving 71 prediabetic men and women (aged 18–65), tested daily supplementation of 250 mg of Eriomin alongside metformin (1000 mg/day).
The results demonstrated improved postprandial glucose metabolism, including a 5% reduction in 2-h OGTT glucose and preservation of active GLP-1 levels.
In contrast, the placebo group exhibited a decline in GLP-1 and increased insulin resistance.
The Eriomin group also showed a 12% reduction in TNF-α, a 7.5% increase in plasma antioxidant capacity (FRAP) and modest but significant decreases in body weight, fat mass and BMI.
Additionally, systolic blood pressure in this group was reduced by 4%, potentially owing to improved antioxidant status and higher dietary potassium intake.
Rob Brewster, President at Ingredients by Nature, said: “We are thrilled with the outcome of this clinical research. Frequently, there are concerns that medications or supplements might adversely impact each other when taken in conjunction."
"This study may offer assurances that no adverse interactions were seen when taken by otherwise healthy but metabolically sensitive individuals."
“This is the fourth published human clinical study conducted on Eriomin, further backing its significant positive effects in supporting glycaemic control, metabolic markers, GLP-1 levels and antioxidant status.”